CD276 and cancer: In addition, a cluster of genes associated with epithelial and cancer cells (for example, CDH1, EPCAM, BIRC5 and CD276) was significantly downregulated in resected tumors with nivolumab/relatlimab-induced MPR (Fig. 3d).